US CDC publishes study showing 91% efficacy of Taiwan's Medigen COVID vaccine
Medigen COVID vaccine reportedly found to be effective in preventing hospitalization from Omicron infections
  
By Keoni Everington, Taiwan News, Staff Writer
2024/02/07 13:39

Medigen packaging and syringes. (FDA image)

TAIPEI (Taiwan News) — The U.S. Centers for Disease Control and Prevention (CDC) is publishing a study demonstrating that Taiwan's locally-developed Medigen COVID vaccine has a high degree of efficacy, comparable to mRNA vaccines.

The CDC's journal Emerging Infections Diseases has accepted a study by Taiwanese scientists into the efficacy of the Medigen COVID vaccine (MVC-COV1901) and will publish the full findings in its March issue. An early release is already online presenting an overview of the study.

According to the study's abstract, after analyzing the vaccine effectiveness (VE) against severe and fatal outcomes post-infection through the administration of three doses of vaccines (two primary and one booster), researchers found that BNT has a VE of 95.8%, Medigen 91.0%, Moderna 81.8%, and AstraZeneca 65.7%. The study's authors concluded that protein subunit vaccines such as Medigen "provide similar protection against SARS-CoV-2­­–associated hospitalization as mRNA vaccines," confirming the efficacy of Taiwan's domestically produced jab.

This study, conducted by a team from the Taiwan Centers for Disease Control, focused on the domestic outbreak of the Omicron variant in 2022 and examined vaccination records for over 23 million individuals. The study used internationally accepted big data statistical analysis to assess the "real-world" efficacy of the vaccines in the study.

The study confirmed that the protective efficacy of receiving three doses of the COVID vaccines is higher. Additionally, it found that mRNA vaccines such as Moderna and BNT, as well as the protein subunit vaccine Medigen, have better and longer-lasting protective efficacy compared to the adenovirus vaccine AstraZeneca, with BNT and Medigen demonstrating protective efficacy of over 90% in preventing moderate to severe illnesses.

Taiwan CDC Deputy Director-General Lo Yi-chun (羅一鈞)\, was cited by Liberty Times as saying that this is also the first international comparison using real-world big data to evaluate mRNA, protein subunit, and adenovirus vector vaccines. Lo said the results confirm that Taiwan's domestically-produced protein subunit vaccine shows comparable effectiveness to mRNA vaccines in protecting against severe illness and death caused by the Omicron variant.

 

共產黨不信神，做壞事無底線❗在全世界殘害大量生命💥「三退運動」讓更多人了解中共，脫離邪惡控制👊 | 明居正

https://www.youtube.com/watch?v=LTgjwpRP7w0

中共中央、地方盲目追求GDP，大舉債做「無效建設」遲早暴雷❗貴州僅2百萬人蓋7條高鐵，宣告破產

https://www.youtube.com/watch?v=yLiwWFeJ1gc

 

#1
明居正憂:中共透過黑社會 對我統戰加劇/台灣大選成第三世界典範 中共害怕台灣民主/
台灣要有所準備 警惕中共誤判/中俄北韓伊朗挑戰國際秩序 第三次世界大戰? / 感謝自由通訊協會授權播出

#2
高端疫苗遭諷「吹箭、符水」 呂秋遠：天底下沒有一個國家的人民，看不起自家疫苗到這種地步...
文｜呂秋遠
▲高端疫苗有經過政府獨立委員會審議通過，而且有數據可供公評。（圖／彭世杰攝）

#4
https://www.medrxiv.org/content/10.1101/2023.06.16.23291455v3

Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines

Sebastian Reinig, Chin Kuo, Chia-Chun Wu, Sheng-yu Huang, Jau-Song Yu, Shin-Ru Shih
...

#5
多種新冠疫苗問世 都靠他的獨門關鍵技術 享受小發現！疫苗大師葛拉漢揭開發心路
 

 

 

文章標籤
全站熱搜
創作者介紹
創作者 魏尚世 的頭像
魏尚世

魏尚世 - (螃蟹收藏、玉石、股票投資、旅遊、美食、電影、手足球、作品...)

魏尚世 發表在 痞客邦 留言(6) 人氣(25)